-
Product Insights
TWS EI Rocio Solar PV Park
TWS EI Rocio Solar PV Park is a solar PV project located in Cesar, Colombia. The project is owned and being developed by TW Consultores Eficiencia Energetica SL. The project is expected to come online in 2026. Empower your strategies with our TWS EI Rocio Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the...
-
Product Insights
PSF EI Copey Solar PV Park
PSF EI Copey Solar PV Park is a solar PV project located in Cesar, Colombia. The project is owned and being developed by Parque Solar Fotovoltaico El Copey SAS. The project is expected to come online in 2027. Empower your strategies with our PSF EI Copey Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
Green City EI Marques Solar PV Park
Green City EI Marques Solar PV Park is a solar PV project located in Aragon, Spain. The project is owned by Green City AG and was developed by Green City AG; Ingenieria y Aplicaciones Solares, S.L.. The project came online in 2020. Empower your strategies with our Green City EI Marques Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EYS-606 in Panuveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EYS-606 in Panuveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EYS-606 in Panuveitis Drug Details: EYS-606 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EI-001 in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EI-001 in Vitiligo report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EI-001 in VitiligoDrug Details:EI-001 is under development for the treatment of Vitiligo and hemophagocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EI-001 in Hemophagocytic Lymphohistiocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EI-001 in Hemophagocytic Lymphohistiocytosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EI-001 in Hemophagocytic Lymphohistiocytosis Drug Details: EI-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EYS-606 in Intermediate Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EYS-606 in Intermediate Uveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EYS-606 in Intermediate Uveitis Drug Details: EYS-606 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EYS-606 in Posterior Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EYS-606 in Posterior Uveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EYS-606 in Posterior Uveitis Drug Details:EYS-606 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EYS-606 in Anterior Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EYS-606 in Anterior Uveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EYS-606 in Anterior UveitisDrug Details:EYS-606 is under development for the treatment of non-infectious...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EI-201 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EI-201 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EI-201 in Cervical CancerDrug Details:EI-201 is under development for the treatment of human...